Comparative Pharmacology
Head-to-head clinical analysis: PROPHENE 65 versus ULTRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPHENE 65 versus ULTRAM.
PROPHENE 65 vs ULTRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
None Documented
None Documented
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic